What Is KPV?
KPV (Lys-Pro-Val) is classified as a anti-inflammatory peptide. Alpha-MSH fragment that potently suppresses NF-κB inflammatory signaling. Reduces pro-inflammatory cytokines and promotes mucosal healing.
It is extensively evaluated in laboratory and clinical settings for its potential to drive gut/injury healing, inflammation reduction. Researchers target KPV for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Excellent profile. Research-only compound with limited human data but strong preclinical safety.
How Does KPV Work?
Alpha-MSH fragment that potently suppresses NF-κB inflammatory signaling. Reduces pro-inflammatory cytokines and promotes mucosal healing.
At the molecular level, KPV operates through pathways characteristic of the Anti-Inflammatory class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with gut/injury healing, inflammation reduction.
Expected Research Timeline
Weeks 2–4
Mucosal healing acceleration; reduced IBD flare symptoms
Months 2–3
Wound healing and IBD remission in study models; sustained anti-inflammatory effect
What Does the Research Say?
The following are key findings from peer-reviewed studies on KPV, indexed on PubMed and equivalent databases:
[1]KPV anti-inflammatory effects in murine colitis
Dalmasso et al. (PLoS One): KPV demonstrates significant anti-inflammatory effects in murine models of inflammatory bowel disease, suppressing NF-κB and MAPK pathways.
Evidence: preclinical[2]KPV suppresses NF-κB signaling in airway epithelium
Study shows KPV inhibits p65RelA nuclear import, suppressing NF-κB inflammatory signaling in airway epithelial cells — relevant to respiratory and gut inflammation.
Evidence: preclinical[3]KPV-loaded nanoparticles for oral IBD treatment
Hyaluronic acid-functionalized nanoparticle delivery of KPV enhances oral bioavailability and anti-inflammatory efficacy in colitis models, supporting clinical translation.
Evidence: preclinical[4]KPV reduces pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
KPV selectively suppresses production of IL-1β, IL-6, IL-12, TNF-α, and IFN-γ in colonic epithelial and immune cells, with effects mediated via intracellular PepT1 transport.
Evidence: preclinicalSafety & Side Effects
Excellent profile. Research-only compound with limited human data but strong preclinical safety.
| Side Effect | Incidence | Severity |
|---|---|---|
| Generally very well-tolerated | Very limited human data | mild |
| Mild GI adjustment | ~5% of users (oral route) | mild |
FDA Status: Not Approved for Human Therapeutic Use
KPV is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is KPV Used?
Route
SubQ
Dose Range
200–200 mcg
Frequency
7x/wk
Cycle
8–8 wk
Timing: Any time
Notes: Often used orally in capsules for gut-specific effects. SubQ for systemic anti-inflammatory.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
KPV vs. Related Compounds
| Compound | Primary Use |
|---|---|
| KPV(this page) | Gut/injury healing, inflammation reduction |
| BPC-157 | Injury recovery, gut healing, tissue repair, reduced inflammation |
| Thymosin Alpha-1 | Immune support, antiviral, recovery |
Where to Source KPV for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is KPV?
KPV is a anti-inflammatory peptide. Alpha-MSH fragment that potently suppresses NF-κB inflammatory signaling. Reduces pro-inflammatory cytokines and promotes mucosal healing.
What are the primary research benefits of KPV?
Published research identifies primary mechanisms targeting: Gut/injury healing, inflammation reduction. These findings come from 4+ peer-reviewed studies indexed in our database.
What is the half-life of KPV?
In published pharmacokinetic data, KPV demonstrates a half-life of approximately 0.5 hours.
Is KPV FDA approved?
KPV is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of KPV?
Reported side effects in published literature include Generally very well-tolerated (Very limited human data), Mild GI adjustment (~5% of users (oral route)). Most are classified as mild in severity.
How is KPV administered?
In research settings, KPV is typically administered via SubQ. Often used orally in capsules for gut-specific effects. SubQ for systemic anti-inflammatory.
Sources
- KPV anti-inflammatory effects in murine colitis. View on PubMed
- KPV suppresses NF-κB signaling in airway epithelium. View on PubMed
- KPV-loaded nanoparticles for oral IBD treatment. View on PubMed
- KPV reduces pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). View on PubMed